• Products
    Investment Suite
    Stocks
    Mutual Funds
    Future and Options
    IPO
    Exchange Traded Funds
    Commodity
    Stockcase (Stock Baskets)
    Currency
    Non Convertible Debentures
    Sovereign Gold Bond
    Exclusive
    NRI Account
    Corporate/HUF Trading Account
    Private Client Group
    Features
    SipIt
    MTF
    Investment Suite
    Exclusive
    Features
  • Platform
    Trading Platforms
    Kotak Neo App & Web
    Nest Trading Terminal
    NEO Trade APIs
    Features and Tools
    MTF
    Securities Accepted as Collateral
    Margin Requirements
    Equity Screeners
    Payoff Analyzer
    Calculators
    SIP Calculator
    Lumpsum Calculator
    Brokerage Calculator
    Margin Calculator
    MTF Calculator
    SWP Calculator
    CAGR Calculator
    Simple Interest Calculator
    ELSS Calculator
    Step up SIP Calculator
    All Calculators
    Trading Platforms
    Features and Tools
    Calculators
  • Pricing
  • Research
    Research Calls
    Long Term calls
    Short Term calls
    Intraday calls
    Derivatives calls
    Pick of the week
    Top Monthly Picks
    Research Reports
    Fundamental Research Report
    Technical Research Report
    Derivative Research Report
    Research Calls
    Research Reports
  • Market
    Stocks
    Share Market Today
    Large Cap
    Mid Cap
    Small Cap
    Indices
    Nifty 50
    Bank Nifty
    FinNifty
    Nifty Midcap India
    VIX
    All Indian Indices
    Mutual Funds
    SBI Mutual Funds
    HDFC Mutual Funds
    Axis Mutual Funds
    ICICI Prudential Mutual Funds
    Nippon India Mutual Funds
    All AMC's
    IPO
    Upcoming IPO
    Current IPO
    Closed IPO
    Recently Listed IPO
    Stocks
    Indices
    Mutual Funds
    IPO
  • Learn
    Stockshaala
    Basics of Stock Market
    Introduction to Fundamental Analysis
    Introduction to Technical Analysis
    Derivatives, Risk management & Option Trading Strategies
    Personal Finance
    Resource
    Market Ready
    Kotak Insights
    Infographic
    Podcast
    Webinars
    Youtube Channel
    Quarterly Results
    Investing Guide
    Demat Account
    Trading Account
    Share Market
    Intraday Trading
    IPO
    Mutual Funds
    Events
    Budget 2025
    Muhurat Trading
    Share Market Holiday
    Market Outlook 2025
    Stockshaala
    Resource
    Investing Guide
    Events
  • Partner
    Business Associates
    Kotak Connect Plus
    Startup connect
  • Support
    FAQs
    Circulars
    Bulletins
    Contact Us
    Forms Download
    Get your Statement

Sumitomo Chemicals India Ltd (SCIL) Q4FY25 Earnings Update: What You Need to Know

  •  3 min read
  •  1,007
  • 1d ago
Sumitomo Chemicals India Ltd (SCIL) Q4FY25 Earnings Update: What You Need to Know

Sumitomo Chemicals India Ltd (SCIL) recently announced its Q4FY25 earnings report, providing a snapshot of its financial health and future outlook. Let’s break down the key points from the report and what it means for investors and the agrochemicals sector.

SCIL's Q4FY25 performance was below market expectations, primarily driven by a decline in exports. Despite this setback, the company demonstrated strong operational metrics for the full fiscal year.

Parameter FY25 Achievement
Gross Margin
Above 40%
EBITDA Margin
Above 20%
Volume Growth
~20% year-on-year (YoY)

This reflects a solid underlying business performance with healthy margins and volume growth, signaling operational efficiency and robust demand domestically.

Looking ahead to FY26, SCIL remains optimistic. The company expects:

  • Early monsoon onset – which benefits sowing activities

  • Stable commodity prices – aiding cost control

  • Increased sowing acreage – boosting product demand

These factors together are expected to create a favourable environment for growth in FY26.

There is a minor revision in earnings estimates for FY26 and FY27, with changes ranging from a slight decrease of 1% to a potential increase of 3%. Although SCIL trades at a premium compared to its peers, it is rated as a "Reduce" stock with a revised Fair Value (FV) of ₹495, slightly down from ₹485. The Current Market Price (CMP) stands at ₹510, indicating a modest downside risk for investors.

SCIL had several bright spots in Q4FY25 and FY25:

  • Strong volume growth: The company reported approximately 20% YoY growth in volumes in FY25.

  • Robust product pipeline: For FY26, SCIL has two patented high-potential molecules expected to drive future revenue.

  • Capital expenditure: The company announced two brownfield capex projects at Bhavnagar and Tarapur to support the parent company's global requirements, signaling long-term investment in capacity expansion.

On the downside, SCIL saw:

  • A 14.7% decline in EBITDA and a 9.2% decline in PAT (Profit After Tax) YoY in Q4FY25.

  • The agrochemicals sector faced de-rating due to macroeconomic concerns and adverse weather impacting demand.

  • Pricing pressures and channel inventory build-up also weighed on financial performance.

For clarity:

  • EBITDA (Earnings Before Interest, Tax, Depreciation & Amortisation) reflects core operational profitability.

  • PAT (Profit After Tax) is the actual net profit available to shareholders.

A decline in these metrics typically signals challenges in either sales volume, pricing, or increased costs.

This simple bar chart illustrates the contrast between strong volume growth and declining profitability in Q4FY25.

Sumitomo Chemicals India Ltd delivered a mixed Q4FY25 performance with volume growth and strategic investments offset by export declines and sector-wide pressures. The company’s outlook for FY26 remains cautiously optimistic, backed by early monsoon and a strong product pipeline.

Investors should weigh the premium valuation against near-term earnings pressure and sector uncertainties. The recommendation is to "Reduce" with a revised Fair Value of ₹495, indicating modest downside risk from the current price.

Investments in securities market are subject to market risks, read all the related documents carefully before investing. This information is purely backed by KSL research analyst based on research recommendation. Kotak Securities Ltd has registration granted by SEBI, Enlistment as RA and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. Registered Office: 27 BKC, C 27, G Block, Bandra Kurla Complex, Bandra (E), Mumbai 400051. SEBI Registration No. INZ000200137 (Member of NSE, BSE, MSE, MCX & NCDEX), Member Id: NSE-08081; BSE-673; MSE-1024; MCX-56285; NCDEX-1262. Research Analyst INH000000586; BSE Enlistment No: 5035 for compliance T&C and disclaimers, Visit https://ddei5-0-ctp.trendmicro.com:443/wis/clicktime/v1/query?url=https%3a%2f%2fbit.ly%2flongdisc&umid=818E14E7-34FE-7906-906B-8F0B1C42A394&auth=d2c41a7df2e2ef1fca42bbbefb1c825d24cf1548-36f3d1caa4f5ef82b030dac05eca909befcec775,

Did you enjoy this article?

0 people liked this article.

What could we have done to make this article better?

Open Your Demat Account Now!
+91 -

Open Your Demat Account Now!
+91 -